DALLAS, TX -- (Marketwired) -- 05/05/15

Vivione Biosciences Inc. ("Vivione" or the "Company") (TSX VENTURE: VBI) Further to the Company's press release dated April 22, 2015, the Company has received TSX Venture Exchange approval for the 30 day price amendment to the exercise price of the 12,000,000 common share purchase warrants (the "Warrants") issued to subscribers as part of the Company's prospectus financing which closed on April 19, 2013. The exercise price of the Warrants will be reduced from CDN$0.35 to CDN$0.155 for a 30 day period (the "Price Amendment"). All other terms of the Warrants will remain the same. The Price Amendment will be effective between May 5 and June 4, 2015 (the "Price Reduction Period") and will begin on the date of the Notice (as described below). The Company will deliver a Notice reflecting the amended exercise price, the exact details of the Price Reduction Period and instructions regarding the exercise of the Warrants to the registered holders of the Warrants.

About Vivione

Formed in 2006 in collaboration with the FDA, Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B system; an integrated system of hardware, software and chemical reagents that quickly and accurately identify, quantify and qualify bacteria and other pathogens in food safety, bio-therapeutics, clinical, industrial and oil & gas environments. For more information, visit www.VivioneBiosciences.com.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

For Additional Information Contact:
Mika Bradford
(817) 705-7221
mbradford@vivionebiosciences.com